Director, Precision Cancer Therapies Program
Dr. Marc Matrana received his medical degree from the LSU School of Medicine in New Orleans. Dr. Matrana completed his internship and residency in internal medicine at Ochsner Medical Center where he served as Chief Medical Resident. He completed training in hematology and medical oncology at MD Anderson Cancer Center in Houston where he received numerous awards and served as both Chief Fellow for Resident Education and overall Chief Fellow.
Dr. Matrana's clinical practice at Ochsner focuses on clinical research, especially first-in-man experimental therapeutics. He is the Director of the Ochsner Precision Cancer Therapies Program, one of the largest phase 1 programs in the Gulf South. He has conducted much ground-breaking research and authored numerous peer-reviewed articles, chapters, and other publications in the field of genitourinary medical oncology.
Dr. Matrana has spoken at conferences around the world on kidney cancer and is a recognized expert in the field. In addition to research and patient care, he is an active medical educator serving in leadership positions with local medical schools, including the University of Queensland School of Medicine/Ochsner Clinical School and the Ochsner Hematology Oncology Fellowship Program.
- Santoni M, Heng D, Bracarda S, Procopio G, Milella M, Porta C, Matrana M, Carteni G, Crabb S, De Giorgi U, Basso U, Masini C, et al. Real-world data on Cabozantinib in previously treated patients with metastatic Renal Cell Carcinoma: focus on prognostic factors and sequences. 2020. Cancers. Vol 12 (1), 84, https://doi.org/10.3390/cancers12010084.
- Vesselinovitch D, Thomas K, Matrana M. Chemotherapy Toxicity confirms Diagnosis of Urachal Carcinoma, 2018. Accepted to Clinical Genitourinary Cancer.
- Gajra A, Karim NA, Mulford DA, Villaruz LC, Matrana MR, Ali HY, Santos ES, Berry T, Ong TJ, Sanford A, Amiri K and Spigel DR (2018) nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2. Front. Oncol. 8:253. doi: 10.3389/fonc.2018.00253.
- Kucharczyk J, Sullivan C, Lu J, Kolomensky A, Peters E, and Matrana M. Prognostic and Predictive Value of Pretreatment Derived Neutrophil-to-Lymphocyte Ratio in Non-Small-Cell Lung Cancer Patients Treated with an Immune Checkpoint Inhibitor. Journal of Cancer Therapy, January 2018 (9) 23-34. DOI: 10.4236/jct.2018.91004.
- Yoo HS, Satti S, Matrana M. Primary Undifferentiated Pleomorphic Sarcoma of the Penis. Ochsner J. 2017 Winter;17(4):434-437. PMID: 29230132
- Kang HC, Gupta S, Wei W, Lu L, Matrana, M, Tannir N, Choi H. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients with Metastatic Renal Cell Carcinoma who are Receiving Salvage Therapy. American Journal of Roentgenology. 2017; PMID: 29064751
- Matrana M, Cook J. Building a Phase 1 Cancer Research Program: Lessons Learned, Progress Made. Accepted for publication by the Ochsner Journal.
- Kucharczyk J, Mandalapu K, Satti S, Matrana M. Outcomes of patients with late relapse metastatic renal cell carcinoma treated with targeted therapies: a single institution experience. Ochsner J. 2017 Winter;17(4):331-334. PMID: 29230117